Project Description

Germany Biomedical laboratory needed for a German biopharmaceutical company searching for an animal model for IBD / Celiac disease.

Our client develops small molecules targeting celiac disease. At present, no animal model for Celiac disease is available to study the efficacy of our client's drug candidates. Since our target - tissue Transglutaminase (TG2) - is a more general marker, highly expressed in IBD, too, we wonder if IBD models can help. The aim is to define the TG2 inhibitor candidate to obtain a dose response curve.